256 related articles for article (PubMed ID: 23831360)
1. Differences in adherence to osteoporosis regimens: a 2-year analysis of a population treated under specific guidelines.
Cheng TT; Yu SF; Hsu CY; Chen SH; Su BY; Yang TS
Clin Ther; 2013 Jul; 35(7):1005-15. PubMed ID: 23831360
[TBL] [Abstract][Full Text] [Related]
2. Incidence and risk of venous thromboembolism among Taiwan osteoporotic fracture population under osteoporosis pharmacological treatments.
Lin TC; Lee CH; Yang CY; Yang YH; Lin SJ
J Clin Endocrinol Metab; 2014 May; 99(5):1599-607. PubMed ID: 24606074
[TBL] [Abstract][Full Text] [Related]
3. Alendronate and raloxifene use related to cardiovascular diseases: differentiation by different dosing regimens of alendronate.
Lu PY; Hsieh CF; Tsai YW; Huang WF
Clin Ther; 2011 Sep; 33(9):1173-9. PubMed ID: 21849210
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of osteoporosis drugs in preventing secondary nonvertebral fractures in Taiwanese women.
Lin TC; Yang CY; Yang YH; Lin SJ
J Clin Endocrinol Metab; 2013 Dec; 98(12):4717-26. PubMed ID: 24081731
[TBL] [Abstract][Full Text] [Related]
5. Gastrointestinal tolerability and patterns of switching in patients treated for primary osteoporosis: the Swedish Adherence Register Analysis (SARA).
Landfeldt E; Lang A; Robbins S; Ström O
Calcif Tissue Int; 2011 Sep; 89(3):234-45. PubMed ID: 21695544
[TBL] [Abstract][Full Text] [Related]
6. Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting.
Downey TW; Foltz SH; Boccuzzi SJ; Omar MA; Kahler KH
South Med J; 2006 Jun; 99(6):570-5. PubMed ID: 16800411
[TBL] [Abstract][Full Text] [Related]
7. Compliance of osteoporotic patients with different treatment regimens.
Segal E; Tamir A; Ish-Shalom S
Isr Med Assoc J; 2003 Dec; 5(12):859-62. PubMed ID: 14689753
[TBL] [Abstract][Full Text] [Related]
8. The risk of osteonecrosis of the jaws in Taiwanese osteoporotic patients treated with oral alendronate or raloxifene.
Chiu WY; Chien JY; Yang WS; Juang JM; Lee JJ; Tsai KS
J Clin Endocrinol Metab; 2014 Aug; 99(8):2729-35. PubMed ID: 24758181
[TBL] [Abstract][Full Text] [Related]
9. Incidence and risk of osteonecrosis of the jaw among the Taiwan osteoporosis population.
Lin TC; Yang CY; Kao Yang YH; Lin SJ
Osteoporos Int; 2014 May; 25(5):1503-11. PubMed ID: 24515577
[TBL] [Abstract][Full Text] [Related]
10. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
[TBL] [Abstract][Full Text] [Related]
11. Prevention and treatment of osteoporosis in women with breast cancer.
Mincey BA; Moraghan TJ; Perez EA
Mayo Clin Proc; 2000 Aug; 75(8):821-9. PubMed ID: 10943237
[TBL] [Abstract][Full Text] [Related]
12. Prescriptions for vitamin D among patients taking antiresorptive agents in Canada.
Hanley DA; Zhang Q; Meilleur MC; Mavros P; Sen SS
Curr Med Res Opin; 2007 Jun; 23(6):1473-80. PubMed ID: 17559742
[TBL] [Abstract][Full Text] [Related]
13. Are there any alternatives to alendronate (Fosamax) for osteoporosis to avoid the risk of osteonecrosis of the jaw?
Wynn RL
Gen Dent; 2007; 55(6):495-8. PubMed ID: 18050572
[No Abstract] [Full Text] [Related]
14. Two years adherence to anti-osteoporotic medications in postmenopausal Israeli women.
Segal E; Ish-Shalom S
Arch Gerontol Geriatr; 2009; 49(3):360-3. PubMed ID: 19147238
[TBL] [Abstract][Full Text] [Related]
15. Low incidence of anti-osteoporosis treatment after hip fracture.
Rabenda V; Vanoverloop J; Fabri V; Mertens R; Sumkay F; Vannecke C; Deswaef A; Verpooten GA; Reginster JY
J Bone Joint Surg Am; 2008 Oct; 90(10):2142-8. PubMed ID: 18829912
[TBL] [Abstract][Full Text] [Related]
16. Cognitive effects of short-term use of raloxifene: a randomized clinical trial.
Buckwalter JG; Geiger AM; Parsons TD; Handler J; Howes J; Lehmer RR
Int J Neurosci; 2007 Nov; 117(11):1579-90. PubMed ID: 17917927
[TBL] [Abstract][Full Text] [Related]
17. Adherence to alendronate in male veterans.
Hansen KE; Swenson ED; Baltz B; Schuna AA; Jones AN; Elliott ME
Osteoporos Int; 2008 Mar; 19(3):349-56. PubMed ID: 17898921
[TBL] [Abstract][Full Text] [Related]
18. Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass.
Recker RR; Kendler D; Recknor CP; Rooney TW; Lewiecki EM; Utian WH; Cauley JA; Lorraine J; Qu Y; Kulkarni PM; Gaich CL; Wong M; Plouffe L; Stock JL
Bone; 2007 Apr; 40(4):843-51. PubMed ID: 17182297
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of different therapeutic regimens on hepatic osteodystrophy in chronic viral liver disease.
Yurci A; Kalkan AO; Ozbakir O; Karaman A; Torun E; Kula M; Baskol M; Gursoy S; Yucesoy M; Bayram F
Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1206-12. PubMed ID: 21971374
[TBL] [Abstract][Full Text] [Related]
20. Adiponectin and leptin serum levels in osteoporotic postmenopausal women treated with raloxifene or alendronate.
Sebastián-Ochoa A; Fernández-García D; Reyes-García R; Mezquita-Raya P; Rozas-Moreno P; Alonso-Garcia G; Muñoz-Torres M
Menopause; 2012 Feb; 19(2):172-7. PubMed ID: 21971209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
